Author

Ningze Zheng

First Affiliated Hospital of Guangzhou Medical UniversityORCID 0000-0002-1065-6586Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Aimin Hui· 2 shared Yingqi XuiD· 2 shared Chunying CheniD· 1 shared Hao GuiD· 1 shared Lei Zhang· 1 shared Rong Cai· 1 shared Weihao Mai· 1 shared Zhicheng HuangiD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

8 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Aimin Hui

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Integrated immunopeptidomics and transcriptomics reveal a cancer-restricted non-canonical HLA class I ligandome in medulloblastoma

Ningze Zheng, Yingqi Xu, Weihao Mai, Aimin Hui

bioRxiv · Sep 28, 2026 · PreprintCancer Biology

Cyclic-thiourea ionizable lipids program multilamellar mRNA-LNPs for sustained expression, frozen-storage stability and potent vaccine immunotherapy

Lei Zhang, Zhicheng Huang, Hao Gu, Ningze Zheng, Chunying Chen, Rong Cai, Aimin Hui

This paper introduces a cyclic-thiourea ionizable lipid (HI-62) that forms multilamellar mRNA-LNPs with sustained expression, stability, and potent vaccine immunotherapy effects.

bioRxiv · Sep 9, 2026 · PreprintBioengineering

Design of a novel multi-epitope mRNA vaccine against BtHKU5-CoV-2 using immunoinformatics

Ningze Zheng, Yingqi Xu

This paper designs a multi-epitope mRNA vaccine against BtHKU5-CoV-2 using immunoinformatics, showing strong antigenicity, immunogenicity, and potential to trigger robust immune responses.

bioRxiv · Sep 2, 2025 · PreprintMicrobiology